Opinions
David Driscoll
Bausch & Lomb Inc.
BOL-N
DON'T BUY
May 08, 2006
Has never been a big fan of this company. Believes they had to restate some earnings which is what caused the stock price to dip.
$44.680
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Has gone through a transition. Was suffering a few years ago when it lost its momentum, R&D lagged. Can see some growth opportunity in their new lens. New president has shaken down the company, cut costs and re-invigorated their R&D. Has exceeded expectations for 13 quarters.
biotechnology
pharmaceutical
Advertising